Miglustat (Generic) (Miglustat CAPSULE) 100 mg/1

Miglustat is an oral iminosugar medication approved by the FDA as an orphan drug for treating Gaucher Type I Disease and Niemann-Pick Disease Type C (NPC). It functions as a glucosylceramide synthase inhibitor, reducing the accumulation of glycosphingolipids in affected tissues. This medication represents a significant therapeutic option for patients with these rare genetic lysosomal storage disorders.

Strength

100 mg/1

Pack Size

6 BLISTER PACK in 1 CARTON (43975-310-83) / 15 CAPSULE in 1 BLISTER PACK (43975-310-08)

Manufacturer / TM Owner

Generic

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Miglustat is indicated for the treatment of Gaucher Type I Disease and Niemann-Pick Disease Type C (NPC), both rare inherited lysosomal storage disorders characterized by abnormal accumulation of glucocerebroside and cholesterol, respectively. The drug is primarily used in adult patients and certain pediatric populations who cannot tolerate or have contraindications to enzyme replacement therapy. Miglustat works by inhibiting glucosylceramide synthase, thereby reducing the synthesis of glycosphingolipids and decreasing their pathological accumulation in organs including the liver, spleen, bone marrow, and central nervous system. The medication is particularly valuable for NPC patients experiencing progressive neurological manifestations such as ataxia, cognitive decline, and vertical supranuclear gaze palsy. Treatment aims to slow disease progression, improve organ function, and enhance quality of life in this vulnerable patient population with limited therapeutic alternatives.

Side Effects

Common side effects of miglustat include gastrointestinal disturbances such as diarrhea, nausea, vomiting, and abdominal pain, which occur in the majority of patients and may be dose-limiting. Tremor, headache, and dizziness are frequently reported neurological effects. Serious adverse events include peripheral neuropathy, which requires baseline and periodic neurological monitoring, and potential immune system effects. Laboratory abnormalities such as thrombocytopenia and elevated liver enzymes may occur. Regular monitoring of complete blood counts, liver function tests, and renal function is essential. Patients should be assessed for signs of peripheral neuropathy during treatment.

Precautions & Warnings

Miglustat is contraindicated in patients with hypersensitivity to the drug or its components. Caution is warranted in patients with renal impairment, as dose adjustment is necessary for creatinine clearance below 60 mL/min. The drug is not recommended in severe hepatic impairment. Pregnancy is a relative contraindication due to limited safety data; women of childbearing potential should use effective contraception. Pediatric use requires careful consideration and monitoring. Patients with pre-existing peripheral neuropathy require baseline assessment and close surveillance. Concurrent use with other potentially neurotoxic agents should be avoided when possible. Regular ophthalmologic examination is recommended due to potential corneal opacities.

Avoid Interactions

Miglustat has limited significant drug-drug interactions but may affect the absorption of other oral medications due to gastrointestinal effects. Concurrent administration with immunosuppressive agents or vaccines may reduce vaccine efficacy. Patients should avoid alcohol consumption, which may exacerbate gastrointestinal side effects. No major interactions with cytochrome P450 inhibitors or inducers have been documented. Patients taking multiple medications should inform healthcare providers, as miglustat's effects on GI motility may impact absorption of other drugs.

Frequently Asked Questions

Miglustat is used to treat Gaucher Type I Disease and Niemann-Pick Disease Type C (NPC), both rare inherited lysosomal storage disorders. It works by reducing the accumulation of harmful lipids in organs and tissues. The medication is particularly important for patients who cannot tolerate enzyme replacement therapy or who have progressive neurological symptoms.

Miglustat is administered orally as a capsule, typically at a dose of 100 mg three times daily for most patients. Dosage adjustments are necessary for patients with renal impairment based on creatinine clearance. The medication should be taken consistently as prescribed by the healthcare provider.

The most common side effects include diarrhea, nausea, vomiting, and abdominal discomfort affecting the gastrointestinal system. Neurological side effects such as tremor, headache, and dizziness may also occur. These effects are often manageable with dose adjustment or supportive care, though some patients may experience peripheral neuropathy requiring monitoring.

Miglustat is available as a generic medication from multiple manufacturers. Originally developed and marketed under the brand name Zavesca, it is now produced by various pharmaceutical companies in generic formulations.

Yes, miglustat has FDA orphan drug designation for both Gaucher Type I Disease and Niemann-Pick Disease Type C. This status recognizes its importance in treating rare diseases affecting small patient populations. Orphan drug designation provides regulatory incentives and support for development of treatments for these uncommon conditions.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.